Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 – The webinar will be available soon Current Status Not Enrolled Price Free Get Started Log In to Enroll Prof. Thierry Facon, Dr. Fredrik Schjesvold Course Content Final Quiz Available on March 28, 2025 7:00 pm
